Report: Administration drafting plan for temporary sale of restricted peptides
The Briefing, October 11, 2026. This week in peptides, in plain English.
Vol. 1 · Issue 03October 11, 2026
An unconfirmed plan on restricted peptides, a case report and warnings on gray-market retatrutide, and a Phase III trial of a synthetic semaglutide.
Regulation · Lead
Washington Post: a draft plan would let some restricted peptides be sold while new rules are written
The Washington Post reported on October 7 that the Trump administration is drafting a plan to let certain restricted peptides be sold temporarily while federal health officials write new rules. The report rests on two unnamed sources. No plan or timeline has been announced.
According to the report, FDA scientists and some medical experts have raised concerns about wider access. The Alliance for Pharmacy Compounding, a trade group, has asked the FDA to let state-licensed pharmacies compound these peptides in the meantime, under safety conditions.
What it means for a reader: this is a report about a plan in progress, not a policy. The report does not say which peptides would be covered, how long a temporary window would last, or who would be allowed to sell them. Nothing has changed yet.
What it does not mean: it does not mean any peptide has been approved, or that any has been judged safe or effective. Even if a temporary pathway appears, it would be a stopgap while rules are written, not a verdict on the science. We will update this thread when there is an official announcement.
Gray-market retatrutide draws a case report and warnings from JAMA and Medscape
A case report published October 7 in BMJ Case Reports describes a woman in her mid-20s admitted with five days of persistent nausea, repeated vomiting, loose stools and very little food or drink. She had received four weekly injections, with the amount increased each time, of an unverified product reported to contain retatrutide. The injections were given in a wellness setting by a self-described life coach with no medical qualification, and she did not think of them as medication.
Tests found no other cause. Her symptoms persisted despite several standard anti-nausea drugs, improved two days after admission and resolved within a week. The authors scored the link as probable using a standard causality tool, and urged clinicians to ask patients directly about injections, peptides, research chemicals, online products and anything recommended by non-medical wellness practitioners.
The same week, a JAMA Medical News article examined the growing black market for two unapproved GLP-1 weight-loss drugs, retatrutide and zenagamtide, and the risks of using them. Medscape ran a doctor's first-person column about a late-night call from a patient using gray-market retatrutide, warning against using the investigational drug outside clinical trials. Zenagamtide remains in testing: a new Phase 1 study registered this week will look at switching people from tirzepatide to it.
Separately, an AJMC explainer covers Eli Lilly's legal dispute with the FDA over whether retatrutide counts as a drug or a biologic. The answer could affect its exclusivity period, when Medicare can negotiate its price, and whether it could ever be compounded.
What it means: retatrutide is investigational and unapproved, and products sold outside trials are unverified. In this case no one could confirm what was actually injected. What it does not mean: a single case report cannot tell us how common reactions like this are, and it says nothing about how retatrutide performs in properly run trials. See the dossier page for background.
A chemically synthesised semaglutide matched Wegovy for weight loss in a Phase III trial
A Phase III trial published October 7 in Diabetes, Obesity and Metabolism found that HD1916, a chemically synthesised semaglutide, produced weight loss equivalent to the reference product, Wegovy. The trial ran at 30 centres in China and randomised 462 adults with obesity and without diabetes to one of the two products, taken once weekly for 44 weeks.
Average weight loss was 13.1% with HD1916 and 14.4% with Wegovy. The difference of 1.35 percentage points fell inside the margin the researchers set in advance for calling the two equivalent. The share of people losing at least 5% of their weight (87.8% vs 90.5%) and at least 10% (68.7% vs 73.6%) was similar, as were reductions in waist size. Side effects were reported by 86.5% and 89.2% of participants respectively, mostly mild to moderate.
What it means: in a controlled trial, a version of semaglutide made by a different production route performed within a pre-agreed range of the branded medicine, with a similar side-effect picture.
What it does not mean: the trial was open-label, so participants knew which product they were taking, and it enrolled only Chinese adults. HD1916 came out slightly lower on every weight measure, although within the equivalence margin. A published trial is not an approval. And it tells us nothing about unregulated products sold as semaglutide, which have not been tested this way.
Semaglutide, explained: borrowing a fullness signal from your own gut
Semaglutide is the GLP-1 drug most people have heard of. It is FDA-approved as the brand medicines Ozempic, for type 2 diabetes, and Wegovy, for weight management. Our dossier covers the compound itself.
It works by mimicking GLP-1, a hormone your gut releases after you eat. That signal does three things. It tells the brain you are full, which is why people describe quieter appetite and less 'food noise'. It slows how fast the stomach empties, so a meal stays with you longer. And it helps the pancreas release insulin only when blood sugar is high, which is why it is also used for blood-sugar management.
Your own GLP-1 is broken down within minutes. Semaglutide carries a fatty-acid tail that keeps it circulating for about a week, which is why it is taken once weekly rather than several times a day. It is used long-term and increased gradually over a period of months.
The evidence base is unusually deep. In the large STEP trials, people lost around 15% of body weight on average over about 16 months, which is why semaglutide is the benchmark that newer drugs are compared against.
The trade-offs follow from how it works. Slowing the gut causes the most common side effects: nausea, diarrhoea, constipation and cramping, usually worst in the week or two after each step up. Severe stomach pain that goes through to the back needs urgent attention because of a rare risk of pancreatitis, as do gallbladder symptoms. It is not for anyone with a personal or family history of medullary thyroid cancer or MEN2. For the full picture, see jointhedailystack.com/peptides/semaglutide/.